Overview

An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
To evaluate efficacy and safety of treatment with XP19986 Sustained Release (SR) Tablet compared to placebo in subjects with symptomatic GERD
Phase:
Phase 2
Details
Lead Sponsor:
Indivior Inc.
XenoPort, Inc.
Treatments:
Arbaclofen placarbil
Baclofen